|
Anticholinergic Syndrome
|
D064807 |
[Adverse drug effects associated with CHOLINERGIC ANTAGONISTS. Clinical features include TACHYCARDIA; HYPERTHERMIA; MYDRIASIS, dry skin and dry mucous membranes, decreased bowel sounds and urinary retention in peripheral anticholinergic syndrome; and HALLUCINATIONS; PSYCHOSES; SEIZURES; and COMA in central anticholinergic syndrome.
] |
|
CUL-6 protein, C elegans
|
C000600610 |
|
|
CID15997213
|
C000600611 |
|
|
2-(nonylsulfonamido)benzoic acid
|
C000600612 |
|
|
4beta,5beta-epoxyxanthatin-1alpha,4alpha-endoperoxide
|
C000600613 |
|
|
TMOD4 protein, zebrafish
|
C000600504 |
|
|
isamine blue
|
C574939 |
|
|
glucagon, deshistidyl(1)-prolyl(4)-glutamyl(9)-
|
C000600505 |
|
|
crotobarin
|
C000600506 |
|
|
crotogoudin
|
C000600507 |
|
|
RGPU-151
|
C000600508 |
|
|
Aagenaes syndrome
|
C535330 |
|
|
RGPU-152
|
C000600509 |
|
|
Aarskog Syndrome
|
C535331 |
|
|
Aase Smith syndrome
|
C535332 |
|
|
kankanoside H2
|
C549975 |
|
|
kankanoside I
|
C549976 |
|
|
1-((1-(4-fluorophenyl)-1H-pyrazol-4-yl)methyl)-4-phenylpiperazine
|
C549977 |
|
|
S-arachidonoyl-2-thioglycerol
|
C549978 |
|
|
N,N-bis-(3-(11H-indolo(3,2-c)quinolin-6-yl)aminopropyl)amine
|
C549979 |
|
